

Edgar Filing: HILDEBRAND DONALD G - Form SC 13D

HILDEBRAND DONALD G
Form SC 13D
October 10, 2006

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

GEOVAX LABS, INC.

(Name of Issuer)

Common Stock

(Title of Securities)

373678101

(CUSIP Number)

Kevin Friedmann, Esq.
Richardson & Patel LLP
10900 Wilshire Boulevard, Suite 500
Los Angeles, CA 90024
(310)-208-1182

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

September 28, 2006

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13D-1(e), 240.12d-1(f) or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of this schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: HILDEBRAND DONALD G - Form SC 13D

CUSIP No. 373678101

-
1. Names of Reporting Persons
IRS Identification Nos. of Above Persons (Entities Only)
DONALD G. HILDEBRAND
-
2. Check the Appropriate Box if a Member of a Group (See Instructions)
- (a)
- (b)
-
3. SEC Use Only
4. Source of Funds (See Instructions) PF
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
-
6. Citizenship or Place of Organization United States
-
- Number of Shares Beneficially Owned by Each Reporting Person With:
7. Sole Voting Power 76,972,107*
8. Shared Voting Power Not Applicable
9. Sole Dispositive Power 76,972,107*
10. Shared Dispositive Power Not Applicable
-
11. Aggregate Amount Beneficially Owned by Each Reporting Person 76,972,107*
-
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
-
13. Percent of Class Represented by Amount in Row (11) 10.6%*
-
14. Type of Reporting Person (See Instructions) IN
-

*This number includes 59,180,847 shares of common stock and two immediately exercisable options to purchase 17,791,260 shares of common stock. The option exercise price is \$0.045 per share. The first option to purchase 8,895,630 shares of common stock will expire in December 2007. The second option to purchase 8,895,630 shares of common stock will expire in February 2009.

Item 1. Security and Issuer

Common stock, \$0.001 par value, of GeoVax Labs, Inc. (the "Issuer"). The Issuer's address is 1256 Briarcliff Road N.E., Emtech Bio Suite 500, Atlanta, Georgia 30306.

Item 2. Identity and Background

(a) This statement is filed by Donald G. Hildebrand (the "Reporting Person").

(b) The Reporting Person's business address is 1256 Briarcliff Road N.E., Emtech Bio Suite 500, Atlanta, Georgia 30306.

Edgar Filing: HILDEBRAND DONALD G - Form SC 13D

(c) The Reporting Person is the Issuer's Chief Executive Officer and President.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding.

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of the United States and a resident of the State of Georgia.

Item 3. Source and Amount of Funds or Other Consideration

This report concerns the issuance of a total of 59,180,847 shares of the Issuer's common stock and two immediately exercisable options to purchase a total of 17,791,260 shares of common stock. The shares of common stock were issued in connection with a merger that took place on September 28, 2006 by and between Dauphin Technology, Inc., GeoVax, Inc. and GeoVax Acquisition Corp. Upon completion of the merger, Dauphin Technology, Inc. (now GeoVax Labs, Inc.) issued shares of its common stock, \$0.001 par value, to the shareholders of GeoVax, Inc. in exchange for their issued and outstanding shares of GeoVax, Inc. common stock. Prior to the merger, the Reporting Person was a holder of 1,995,840 shares of GeoVax, Inc. common stock and two immediately exercisable options, each for the purchase of 300,000 shares of common stock. The 1,995,840 shares of GeoVax, Inc. common stock were issued to the Reporting Person in exchange for cash in the amount of \$199.58. The cash paid for the common stock was from the Reporting Person's personal funds.

Item 4. Purpose of Transaction

The purpose of this transaction was to effectuate the merger between Dauphin Technology, Inc. and GeoVax, Inc.

The acquisition of the shares described herein was done solely in conjunction with the merger. As of the date of this report, the Reporting Person does not have any plan or proposal

(i) to acquire additional securities of the Issuer or to dispose of securities of the Issuer, although he may do either of these in the future;

(ii) that would result in an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer;

(iii) that would result in the sale or transfer of a material amount of assets of the Issuer;

(iv) to change the composition of the Issuer's board of directors or management, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(v) that would result in any material change in the present capitalization or dividend policy of the Issuer;

(vi) that would result in any other material change in the Issuer's business or corporate structure;

Edgar Filing: HILDEBRAND DONALD G - Form SC 13D

(vii) that would result in any change in the Issuer's charter, bylaws or instruments corresponding thereto in order to impede the acquisition of control of the Issuer;

(viii) that would cause a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(ix) that would cause a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(x) that would result in any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer

The Reporting Person beneficially owns a total of 76,972,107 shares, or approximately 10.6%, of the Issuer's common stock. This number consists of 59,180,847 shares of common stock and fully vested options to purchase an

additional 17,791,260 shares of the Issuer's common stock. The number of shares shown as beneficially owned by the Reporting Person are calculated pursuant to Rule 13d-3(d)(1) of the Securities Exchange Act of 1934. Under Rule 13d-3(d)(1), shares not outstanding that are subject to options, warrants, rights or conversion privileges exercisable within 60 days are deemed outstanding for the purpose of calculating the number and percentage owned by the Reporting Person. The Reporting Person has the sole power to vote and to dispose of the shares he beneficially owns. The Reporting Person did not effect any transactions in the Issuer's common stock during the past 60 days, other than the exchange of GeoVax, Inc. common stock for the Issuer's common stock, which exchange was done in conjunction with the merger. No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting Person's common stock.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Not applicable.

Item 7. Material to Be Filed as Exhibits

None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

October 5, 2006

/s/ Donald G. Hildebrand

Donald G. Hildebrand
